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In-Stent Restenosis Via Network
Meta-Analysis (NMA)?
Simple Methods Any Interventionalist Can Use to Assess
NMA Quality and a Call for Better NMA Presentation*Stephen G. Ellis, MDI n this issue of JACC: Cardiovascular Interven-tions, Lee et al. (1) present the results of aBayesian network meta-analysis (NMA) to assess
the relative efﬁcacy of drug-eluting stents (DES),
drug-eluting balloons (DEB), and plain old balloon an-
gioplasty (POBA) used to treat in-stent restenosis
(ISR), using target lesion revascularization (TLR) as
the outcome measure and 11 randomized, controlled
trials as the data source. They conclude that both
DES and DEB reduce TLR by w75% to 80% compared
with POBA. This is supported by data from angio-
graphic follow-up. Safety issues (death and myocar-
dial infarction) were also considered. They go on to
assess the probability of the best treatment and
conclude that it is most likely to be treatment with
DEB (60% likelihood).SEE PAGE 382I suspect most cardiologists experience some form
of “brain freeze” when confronted with the results of
an NMA, and I suspect most of us simply jump to the
conclusions and hope the paper was well enough
refereed so they are valid. Sadly, that may not always
be true (2).
Fortunately, there are several excellent and read-
able reviews on the topic, not only in statistical
journals (3–6), but also mainstream journals such as*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the Cleveland Clinic, Cleveland, Ohio. Dr. Ellis has reported that he
has no relationships relevant to the contents of this paper to disclose.the British Medical Journal (7) and Annals of Internal
Medicine (8,9) that demystify the topic.
In short, NMAs are used to draw comparisons
between outcomes of treatments that have been
either directly or indirectly compared by making use
of comparison treatments they share in common.
Here is a simple step-by-step way to begin to judge
the strength of evidence and some suggestions about
how to present NMAs to make it even easier to make
that assessment (skip to the last paragraph if you
have no interest in NMAs).
1. Almost all NMA papers contain a graph showing
“network geometry”—the treatments analyzed and
connectivity of the trial data used (see Figure 1 in
the Lee et al. (1) paper). Check the number of lines
(trials) between the nodes (treatments to be
compared) and whether the lines directly connect
the trials or run through other trials. The more the
connecting lines and more direct the connections,
the better the strength of evidence is.
2. Downgrade comparisons made primarily by un-
derpowered trials (graphic presentation can be
improved to make this easy to visualize; see
Figure 1).
3. Heterogeneity of trial design and results are
killers for NMA. Differences in inclusion criteria
or treatment application (e.g., low risk vs. all-
comers DES trials, heparin dose, and bivalirudin
treatment duration in ST-segment elevation
myocardial infarction medication trials) can make
the results of indirect comparisons very different
from those of direct comparisons (which obvi-
ously do not suffer have this problem). This is
termed incoherence. Check to see that authors
Ellis J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 3 , 2 0 1 5
When Is a Meta-Analysis Good Enough? M A R C H 2 0 1 5 : 3 9 5 – 7
396speciﬁcally deal with this issue by comparing re-
sults of direct and indirect comparisons between
2 treatments (when possible). Heterogeneity of
trial results per se should also be assessed by
Cochran’s Q or I2 testing (signiﬁcant differences
are suggested by values of p < 0.1 for simple
NMAs or p < 0.15 for complex NMAs, or I2 >50%,
respectively). Authors can make this easier by
modifying their network geometry graphs
(Figure 1).
4. Make sure random-effects modeling, rather
than ﬁxed-effects modeling was used (the latter
assumes that there is a negligible amount of
heterogeneity, which is usually incorrect).
5. Be skeptical about claims for ranking treatments in
order of effect because as they are particularly
prone to error (7).
Suggestions for better “network geometry” graphic
depiction (Figure 1) are the following:
1. Distinguish trials adequately powered for the
outcome of interest (e.g., dark lines) from under-
powered trials (e.g., lighter lines) (some authors do
this already).
2. Distinguish trials with the exact population of in-
terest and same design (e.g., solid lines) from trialsFIGURE 1 NMA Network Geometry Depictions
(A) Network geometry showing the relationships of trials with 5
treatments (1 to 5) and placebo (P). Each trial between 2 treat-
ments is indicated by a solid line between them; 11 trials total.
(B) Same overall conﬁguration as in A. Modiﬁed to provide
additional information indicated by the key. Varying darkness
of the connection line has been suggested by others. NMA ¼
network meta-analysis.with slightly different populations or design (e.g.,
dotted lines). See the issue of incoherence dis-
cussed previously.
A suggestion for a better “effects summary”
depiction is to note to the side of each estimate of
effect the strength of evidence on which the estimate
rests (strong, medium, weak).
With that said, clearly there are other nuisances of
NMAs to consider, including more detailed assess-
ment of the quality of the trials included, and a good
statistician should be asked to referee papers with
NMAs.
Back to the issue at hand, what does this anal-
ysis add to our understanding of how to treat
ISR? First, the authors’ general approach to NMAs
(searching PubMed and other websites, using a
Bayesian approach with WinBUGS software) is
standard in the ﬁeld. Their use of a random-effects
model, comparison of direct- and indirect-effect
estimates using node-splitting, reporting statistical
heterogeneity with I2, and sensitivity testing is
laudable.
Second, reviewing their Figure 1B, one sees at
least 3 trials bridging each treatment, which is
strength.
Conversely, there are some issues of concern. First,
including underpowered trials undercuts the reli-
ability of the results. Because of the large expected
difference in TLR between POBA and the other
treatments, trials comparing these treatments can be
small (e.g., 43 patients per group, assuming 40% vs.
10% TLR with 85% power). However, DEB versus DES
trials, attempting to see differences on the order of
15% versus 10% with the same power, need to include
w820 patients in each group, more patients per group
than are available in aggregate in the NMA that we are
evaluating. Statistical power for low-frequency
events such as death and myocardial infarction is
even worse. Finally, NMAs combining results with
some trials having no events at all (e.g., no deaths or
no myocardial infarctions) are notorious for unstable
p values.
Second, there are multiple reasonable concerns
that can be raised about heterogeneity that weaken
their results. For incoherence, differences in study
design including treating both BMS and DES
ISR using a variety of different DES (principally
ﬁrst-generation DES) and lumping their results
together, mixing TLR and target vessel revasculari-
zation, and using data from differing lengths of
follow-up all are problems. Further, patient level
data from which to adjust for confounders was not
available. With regard to statistical heterogeneity,
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397for many comparisons, I2 values exceed the 50%
threshold.
To summarize, the magnitude of DEB and DES
beneﬁt for TLR compared with POBA is such that,
despite the concerns raised, it is most certainly cor-
rect in order and general magnitude. Conclusions
regarding the relative efﬁcacy and safety of DEB andDES in this circumstance, particularly generalizing to
current devices, are premature.
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